Darren C. Phillips
AbbVie (United States)(US)Biocompatibles (United Kingdom)(GB)
Publications by Year
Research Areas
Cell death mechanisms and regulation, Cancer-related Molecular Pathways, Acute Myeloid Leukemia Research, Protein Degradation and Inhibitors, MicroRNA in disease regulation
Most-Cited Works
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy(2015)535 cited
- → Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)(2015)427 cited
- → Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity(2014)328 cited
- → 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis(2020)190 cited
- → The anti‐inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species(2003)183 cited